Targeting cancer cell survival mechanisms in aggressive breast cancer
Official title: Direct targeting of HIF1a-driven transcription in TNBC with engineered STRs
Funded at University of Chicago · NIH-11094899 · Data updated 2026-11-12
This study is exploring new treatments for triple negative breast cancer by finding ways to block certain proteins that help cancer cells survive, which could lead to better options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $667,792 |
| NIH project number | 5R01CA292876-02 |
| Project ID | NIH-11094899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are seeking new treatment options.
✕Less likely to help
Patients with non-triple negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for triple negative breast cancer (TNBC) by targeting specific transcription factors that help cancer cells survive under stress. The approach involves creating synthetic transcriptional repressors that can inhibit the activity of these factors, specifically HIF1a and XBP1, which are crucial for tumor growth and metastasis. By blocking their ability to bind to DNA, the researchers aim to disrupt the cancer cells' protective mechanisms, potentially leading to more effective treatments. Patients may benefit from new therapeutic options that directly target the underlying biology of their cancer.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for patients with triple negative breast cancer.
How similar studies have gone: Other research has shown promise in targeting transcription factors in cancer, suggesting that this approach could be a viable strategy for treating TNBC.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Moellering, Raymond E — University of Chicago
- Study coordinator: Moellering, Raymond E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.